Professor of Medicine
Keck School of Medicine
University of Southern California
Los Angeles, California
- Metabolic complications of HIV therapies
- Effects of HIV-1 protease inhibitors on glucose metabolism and endothelial function
- Metabolic complications subtopics: glucose metabolism, insulin resistance, and diabetes
- Evolution and treatment of lipid disorders
Dr Dubé is an attending physician at the Los Angeles County-USC Medical Center in Los Angeles. He is the Associate Director of the 5P21 Rand Schrader Health and Research Center at LA County-USC Medical Center. Dr Dubé is also a Professor of Medicine at USC's Keck School of Medicine.
- Member, National HIV/AIDS Nutrition Guidelines Expert Panel, DHHS
- Member, Metabolic Complications Guidelines Panel, IAS–USA
- Member, NHLBI Working Group on Cardiovascular Complications in HIV/AIDS
- Writing Group Chair, American Heart Association and the American Academy of HIV Medicine Cardiovascular Disease/HIV Advisory Working Group
- Boston University, BA Medical Sciences (1983)
- Boston University School of Medicine, MD (1983)
- University of Southern California, Internal Medicine (1986)
- University of Southern California, Infectious Diseases (1992)
- Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet. 1997;350:713-714.
- Dubé MP, Edmondson-Melançon H, Qian D, et al. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquir Immun Defic Syndr. 2001;27:130-134.
- Dubé MP, Qian D, Edmondson-Melançon H, et al. Prospective, 48-week, intensive study of metabolic changes associated with 48 weeks of amprenavir-based therapy. Clin Infect Dis. 2002;35:475-481.
- Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, et al. Guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy. Recommendations of the HIV Medical Association of the Infectious Disease Society of America. Clin Infect Dis. 2003;37:613-627.
- Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1808-1819.
- Shankar SS, Dubé MP, Gorski JC, Klaunig JE, Steinberg HO. Chronic indinavir administration impairs endothelial function in healthy HIV-negative men. Am Heart J. 2005;150:933.e1-933.e7.
- Mulligan K, Parker RA, Komarow L, Grinspoon SK, Tebas P, Robbins GK, Roubenoff R, Dubé MP. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. JAIDS. 2006;41:1-8.
- Dubé MP, Wu JW, Aberg JA, Deeg MA, Alston-Smith BL, McGovern ME, Lee D, Shriver SL, Martinez AI, Greenwald ML, Stein JH. Safety and efficacy of extended-release niacin for the treatment of dyslipidemia in patients with human immunodeficiency virus infection: AIDS Clinical Trials Group Study A5148. Antivir Ther. 2006;11:1081-1089.
- Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P. Long-term body fat outcomes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of ACTG 384. JAIDS. 2007;45:508-514.
- Dubé MP, Gorski JC, Shen C. Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects. Cardiovasc Toxicol. 2008;8:15-22.
- Dubé MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with four weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy HIV-uninfected subjects: A placebo-controlled trial. Clin Infect Dis. 2008; in press.
- Dubé MP, Lipshultz SE, Fichtenbaum C, Fisher SD, Greenberg R, Schecter A. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation. 2008; in press.